Aktienbewertung
Konkurrenz
| Ticker | Preis | Prognose 1J | Prognose 2J | Börsenwert | Div Yld | Wachstumsrate |
|---|---|---|---|---|---|---|
|
NYSE:LLY
Eli Lilly and
|
783.18 | -49,6% | -28,91% | 705.179,49 | 0,68% | 2,63% |
|
NYSE:MRK
Merck
|
130.99 | -9,88% | 3,33% | 331.772,3 | 2,35% | -19,03% |
|
NYSE:ABBV
AbbVie
|
164.56 | -22,18% | -11,89% | 290.591,2 | 3,73% | 7,03% |
|
LSE:AZN
AstraZeneca PLC
|
120.96 | 19,03% | 41,77% | 187.516,43 | 2,01% | 15,98% |
|
SWX:ROG
Roche Holding
|
237.10 | 25,34% | 40,63% | 191.277,25 | 4,05% | 0,43% |
|
NYSE:PFE
Pfizer
|
28.53 | 8,9% | 39,33% | 161.667,9 | 5,87% | -9,31% |
|
NasdaqGS:REGN
Regeneron Pharmaceuticals
|
987.27 | -29,95% | -23,98% | 106.512,12 | 0% | 13,9% |
|
NYSE:BMY
Bristol-Myers Squibb
|
43.36 | 64,24% | 74,73% | 87.895,06 | 5,45% | 13,54% |
|
SHSE:600276
Jiangsu Hengrui Medicine
|
43.81 | 43,44% | 82,51% | 278.568,51 | 0,45% | 1,61% |
|
SEHK:1093
CSPC Pharmaceutical Group
|
6.77 | 32,17% | 48,19% | 80.069,71 | 4,23% | 19,3% |
|
SEHK:1801
Innovent Biologics
|
40.15 | 0% | 0% | 65.978,98 | 0% | 0% |
|
SHSE:600196
Shanghai Fosun Pharmaceutical (Group)
|
23.81 | 90,1% | 181,68% | 58.251,4 | 1,14% | -2,01% |
|
SEHK:9926
Akeso
|
49.25 | 0% | 0% | 43.725,79 | 0% | -.262,86% |
|
SZSE:300003
Lepu Medical Technology (Beijing)
|
16.04 | 172,68% | 235,58% | 28.700,51 | 2,08% | 0,34% |
|
SEHK:1877
Shanghai Junshi Biosciences
|
13.40 | 0% | 0% | 28.369,43 | 0% | 0% |
|
SHSE:600062
China Resources Double-Crane Pharmaceutical
|
22.92 | 0% | 0% | 23.788,79 | 1,14% | 13,43% |
|
NasdaqGM:ZLAB
Zai Lab
|
20.84 | 0% | 0% | 1.992,11 | 0% | 0% |
|
SEHK:9969
InnoCare Pharma
|
5.07 | 0% | 0% | 10.242,21 | 0% | 0% |
|
SEHK:2696
Shanghai Henlius Biotech
|
17.86 | 0% | 0% | 8.869,84 | 0% | -.171,88% |
|
SEHK:9966
Alphamab Oncology
|
5.20 | 0% | 0% | 4.583,01 | 0% | 0% |
